Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Alan Menter; Neil J. Korman; Craig A. Elmets; Steven R. Feldman; Joel M. Gelfand; Kenneth B. Gordon; Alice Gottlieb; John Y.M. Koo; Mark Lebwohl; Craig L. Leonardi; Henry W. Lim; Abby S. Van Voorhees; Karl R. Beutner; Caitriona Ryan; Reva Bhushan

doi:10.1016/j.jaad.2010.11.055

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Alan Menter, Neil J. Korman, Craig A. Elmets, Steven R. Feldman, Joel M. Gelfand, Kenneth B. Gordon, Alice Gottlieb, John Y.M. Koo, Mark Lebwohl, Craig L. Leonardi, Henry W. Lim, Abby S. Van Voorhees, Karl R. Beutner, Caitriona Ryan, Reva Bhushan^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

440 Scopus citations

Abstract

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.

Original language	English (US)
Pages (from-to)	137-174
Number of pages	38
Journal	Journal of the American Academy of Dermatology
Volume	65
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2010.11.055
State	Published - Jul 2011

Funding

Steven R. Feldman, MD, PhD: Dr Feldman served on the Advisory Board and was investigator and speaker for Galderma, Stiefel, Warner Chilcott, Abbott Labs, and Astellas receiving grants and honoraria; served on the Advisory Board for Photomedex receiving stock options; received grants from National Psoriasis Foundation and Dermatology Foundation, Coria, ASDS, Aventis Pharma Ortho Pharma, Pharmaderm, and Roche Dermatology; was an investigator and speaker for Amgen, Centocor, Connetics, and Genentech receiving grants and honoraria; was a speaker and consultant for Bristol-Myers Squibb Derm receiving grants; a speaker for Novartis and 3M receiving grants; and a consultant and speaker for Bristol-Myers Squibb Derm and Biogenidec receiving grants. He received separate department funding from Acuderm, Advanced Tissue Sciences, Allergan, Aventis, Bristol-Myers Squibb, Combe, Curatek, Ferndale, Fujisawa, Hermal, Hoffman LaRoche, Galderma, Genderm, Glaxo Wellcome, Hill, Janssen, Mayrand, Neostrata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Proctor & Gamble, RJR Nabisco, Schering-Plough, Shelton, SmithKline, Stiefel, 3M, United Catalyst, Upjohn and Wolff Systems.

Keywords

adalimumab
alefacept
biologics
case studies
clinical guidelines for psoriasis
combination therapy
comorbidities
dermatology
etanercept
gaps in knowledge
gaps in research
golimumab
guidelines
inflammation
infliximab
methotrexate
narrowband
phototherapy
psoralen plus ultraviolet A
psoriasis
psoriatic arthritis
skin disease
systemic therapy
therapeutic recommendations
topical treatments
traditional systemic therapy
tumor necrosis factor-alfa
ustekinumab

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2010.11.055

Fingerprint

Dive into the research topics of 'Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions'. Together they form a unique fingerprint.

Cite this

Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., Lim, H. W., Van Voorhees, A. S., Beutner, K. R., Ryan, C., & Bhushan, R. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology, 65(1), 137-174. https://doi.org/10.1016/j.jaad.2010.11.055

@article{d93c6aa24efa486fb7a02c71fdef071d,

title = "Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions",

abstract = "Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.",

keywords = "adalimumab, alefacept, biologics, case studies, clinical guidelines for psoriasis, combination therapy, comorbidities, dermatology, etanercept, gaps in knowledge, gaps in research, golimumab, guidelines, inflammation, infliximab, methotrexate, narrowband, phototherapy, psoralen plus ultraviolet A, psoriasis, psoriatic arthritis, skin disease, systemic therapy, therapeutic recommendations, topical treatments, traditional systemic therapy, tumor necrosis factor-alfa, ustekinumab",

author = "Alan Menter and Korman, {Neil J.} and Elmets, {Craig A.} and Feldman, {Steven R.} and Gelfand, {Joel M.} and Gordon, {Kenneth B.} and Alice Gottlieb and Koo, {John Y.M.} and Mark Lebwohl and Leonardi, {Craig L.} and Lim, {Henry W.} and {Van Voorhees}, {Abby S.} and Beutner, {Karl R.} and Caitriona Ryan and Reva Bhushan",

note = "Funding Information: Steven R. Feldman, MD, PhD: Dr Feldman served on the Advisory Board and was investigator and speaker for Galderma, Stiefel, Warner Chilcott, Abbott Labs, and Astellas receiving grants and honoraria; served on the Advisory Board for Photomedex receiving stock options; received grants from National Psoriasis Foundation and Dermatology Foundation, Coria, ASDS, Aventis Pharma Ortho Pharma, Pharmaderm, and Roche Dermatology; was an investigator and speaker for Amgen, Centocor, Connetics, and Genentech receiving grants and honoraria; was a speaker and consultant for Bristol-Myers Squibb Derm receiving grants; a speaker for Novartis and 3M receiving grants; and a consultant and speaker for Bristol-Myers Squibb Derm and Biogenidec receiving grants. He received separate department funding from Acuderm, Advanced Tissue Sciences, Allergan, Aventis, Bristol-Myers Squibb, Combe, Curatek, Ferndale, Fujisawa, Hermal, Hoffman LaRoche, Galderma, Genderm, Glaxo Wellcome, Hill, Janssen, Mayrand, Neostrata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Proctor & Gamble, RJR Nabisco, Schering-Plough, Shelton, SmithKline, Stiefel, 3M, United Catalyst, Upjohn and Wolff Systems. ",

year = "2011",

month = jul,

doi = "10.1016/j.jaad.2010.11.055",

language = "English (US)",

volume = "65",

pages = "137--174",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "1",

}

Menter, A, Korman, NJ, Elmets, CA, Feldman, SR, Gelfand, JM, Gordon, KB, Gottlieb, A, Koo, JYM, Lebwohl, M, Leonardi, CL, Lim, HW, Van Voorhees, AS, Beutner, KR, Ryan, C & Bhushan, R 2011, 'Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions', Journal of the American Academy of Dermatology, vol. 65, no. 1, pp. 137-174. https://doi.org/10.1016/j.jaad.2010.11.055

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. / Menter, Alan; Korman, Neil J.; Elmets, Craig A. et al.
In: Journal of the American Academy of Dermatology, Vol. 65, No. 1, 07.2011, p. 137-174.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Guidelines of care for the management of psoriasis and psoriatic arthritis

T2 - Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

AU - Menter, Alan

AU - Korman, Neil J.

AU - Elmets, Craig A.

AU - Feldman, Steven R.

AU - Gelfand, Joel M.

AU - Gordon, Kenneth B.

AU - Gottlieb, Alice

AU - Koo, John Y.M.

AU - Lebwohl, Mark

AU - Leonardi, Craig L.

AU - Lim, Henry W.

AU - Van Voorhees, Abby S.

AU - Beutner, Karl R.

AU - Ryan, Caitriona

AU - Bhushan, Reva

N1 - Funding Information: Steven R. Feldman, MD, PhD: Dr Feldman served on the Advisory Board and was investigator and speaker for Galderma, Stiefel, Warner Chilcott, Abbott Labs, and Astellas receiving grants and honoraria; served on the Advisory Board for Photomedex receiving stock options; received grants from National Psoriasis Foundation and Dermatology Foundation, Coria, ASDS, Aventis Pharma Ortho Pharma, Pharmaderm, and Roche Dermatology; was an investigator and speaker for Amgen, Centocor, Connetics, and Genentech receiving grants and honoraria; was a speaker and consultant for Bristol-Myers Squibb Derm receiving grants; a speaker for Novartis and 3M receiving grants; and a consultant and speaker for Bristol-Myers Squibb Derm and Biogenidec receiving grants. He received separate department funding from Acuderm, Advanced Tissue Sciences, Allergan, Aventis, Bristol-Myers Squibb, Combe, Curatek, Ferndale, Fujisawa, Hermal, Hoffman LaRoche, Galderma, Genderm, Glaxo Wellcome, Hill, Janssen, Mayrand, Neostrata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Proctor & Gamble, RJR Nabisco, Schering-Plough, Shelton, SmithKline, Stiefel, 3M, United Catalyst, Upjohn and Wolff Systems.

PY - 2011/7

Y1 - 2011/7

N2 - Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.

AB - Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.

KW - adalimumab

KW - alefacept

KW - biologics

KW - case studies

KW - clinical guidelines for psoriasis

KW - combination therapy

KW - comorbidities

KW - dermatology

KW - etanercept

KW - gaps in knowledge

KW - gaps in research

KW - golimumab

KW - guidelines

KW - inflammation

KW - infliximab

KW - methotrexate

KW - narrowband

KW - phototherapy

KW - psoralen plus ultraviolet A

KW - psoriasis

KW - psoriatic arthritis

KW - skin disease

KW - systemic therapy

KW - therapeutic recommendations

KW - topical treatments

KW - traditional systemic therapy

KW - tumor necrosis factor-alfa

KW - ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=79958800583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958800583&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.11.055

DO - 10.1016/j.jaad.2010.11.055

M3 - Article

C2 - 21306785

AN - SCOPUS:79958800583

SN - 0190-9622

VL - 65

SP - 137

EP - 174

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology. 2011 Jul;65(1):137-174. doi: 10.1016/j.jaad.2010.11.055

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this